PCRX
Pacira BioSciences, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+20/100
Last price
24.76
▼ 0.29 (1.16%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
25.05
Prev close
25.05
Day high
25.25
Day low
24.56
Volume
493.12K
Market cap
$986.98M
P/E (TTM)
70.74
52W range
18.80 – 27.66
Day trading desk
Gap from prior close
+0.00%
Prior close 25.05
VWAP
24.78
-0.08% from price
Relative volume
1.41×
Normal
Session range
5.26%
24.13 – 25.40
Position in range
50%
Mid range
ATR (14D)
0.78
3.17% of price
Prior day high
25.71
PDH
Prior day low
24.83
PDL
Bid / ask spread
—
Quote not published
Session volume
820.04K
Avg 579.60K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.47%
-5.4%
1M
-6.03%
-7.2%
3M
-2.98%
-7.5%
6M
+9.90%
-8.3%
YTD
-4.33%
-18.6%
1Y
-0.32%
-16.7%
3Y
-19.30%
-101.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PCRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+25.42K
Net buying
Buy transactions
9
69.83K shares
Sell transactions
5
44.41K shares
Net transactions
+14
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
693.20K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 17, 26 | SLONIN JONATHAN Officer |
SELL | 3.04K | $70.62K | Direct |
| Jun 11, 26 | RIKER LAUREN BULLARO Officer |
SELL | 6.12K | $143.70K | Direct |
| Jun 10, 26 | YANG MICHAEL J. Director |
STOCK | 6.41K | $0 | Direct |
| Jun 10, 26 | FROIMSON MARK Director |
STOCK | 6.41K | $0 | Direct |
| Jun 10, 26 | HIRAWAT SAMIT Director |
STOCK | 6.41K | $0 | Direct |
| Jun 10, 26 | CHRISTIE CHRISTOPHER J. Director |
STOCK | 6.41K | $0 | Direct |
| Jun 10, 26 | YOUNG ALETHIA R. Director |
STOCK | 6.41K | $0 | Direct |
| Jun 10, 26 | BIGAL MARCELO M.D., PH.D. Director |
STOCK | 6.41K | $0 | Direct |
| Jun 10, 26 | BREGE LAURA A Director |
STOCK | 6.41K | $0 | Direct |
| Jun 4, 26 | WILLIAMS KRISTEN MARIE Officer |
SELL | 10.26K | $228.47K | Direct |
| Apr 23, 26 | CROSS SHAWN M. Chief Financial Officer |
CONVERSION | 12.94K | $212.88K | Direct |
| Apr 23, 26 | CROSS SHAWN M. Chief Financial Officer |
SELL | 12.94K | $325.60K | Direct |
| Apr 22, 26 | CROSS SHAWN M. Chief Financial Officer |
CONVERSION | 12.06K | $198.37K | Direct |
| Apr 22, 26 | CROSS SHAWN M. Chief Financial Officer |
SELL | 12.06K | $302.60K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BREGE LAURA A |
Director | 30.12K | Stock Award(Grant) |
CROSS SHAWN M. |
Chief Financial Officer | 105.34K | Conversion of Exercise of derivative security |
FROIMSON MARK |
Director | 26.54K | Stock Award(Grant) |
GAUGLER DARYL |
Chief Operating Officer | 115.44K | Stock Award(Grant) |
KRONENFELD MARK A |
Director | 34.90K | Stock Award(Grant) |
LEE FRANK DON |
Chief Executive Officer | 660.83K | Stock Award(Grant) |
RIKER LAUREN BULLARO |
Officer | 62.28K | Sale |
SLONIN JONATHAN |
Officer | 216.38K | Sale |
TEEHAN BRENDAN |
Officer | 100.93K | Stock Award(Grant) |
WILLIAMS KRISTEN MARIE |
Officer | 167.06K | Sale |
Fundamentals
Market cap$986.98M
Enterprise value$1.15B
Revenue (TTM)$746.16M
Gross profit$591.01M
EBITDA$123.97M
Net income$14.64M
EPS (TTM)$0.35
Free cash flow$98.34M
Total cash$251.03M
Total debt$412.12M
Book value / share$16.87
Shares outstanding39.86M
Float36.19M
Short % of float27.27%
Dividend yield0.00%
Beta (5Y)0.25
Valuation & profitability ratios
Trailing P/E70.74
Forward P/E7.19
PEG ratio0.68
Price / sales—
Price / book1.47
EV / revenue1.54
EV / EBITDA9.26
Gross margin79.21%
Operating margin6.17%
Profit margin1.96%
Return on equity2.05%
Return on assets1.48%
Debt / equity61.33
Current ratio5.04
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $726.41M | $700.97M | $674.98M | $666.82M | +3.6% |
| Operating revenue | $726.41M | $700.97M | $674.98M | $666.82M | +3.6% |
| Cost of revenue | $149.75M | $170.43M | $184.67M | $199.29M | -12.1% |
| Gross profit | $576.66M | $530.54M | $490.31M | $467.53M | +8.7% |
| Research & development | $117.31M | $81.58M | $76.26M | $84.80M | +43.8% |
| Selling, general & admin | $368.76M | $294.10M | $269.44M | $254.52M | +25.4% |
| Total operating expense | $557.47M | $440.67M | $402.63M | $407.50M | +26.5% |
| Operating income | $19.19M | $89.87M | $87.67M | $60.02M | -78.6% |
| Net interest income | $5.29M | $3.12M | -$8.86M | -$35.43M | +69.4% |
| Pre-tax income | $16.87M | -$63.11M | $61.70M | $13.30M | +126.7% |
| Tax provision | $9.84M | $36.45M | $19.75M | -$2.61M | -73.0% |
| Net income | $7.03M | -$99.56M | $41.95M | $15.91M | +107.1% |
| Net income to common | $7.03M | -$99.56M | $41.95M | $15.91M | +107.1% |
| Basic EPS | 0.16 | -2.15 | 0.91 | 0.35 | +107.4% |
| Diluted EPS | 0.16 | -2.15 | 0.89 | 0.34 | +107.4% |
| EBIT | $31.48M | -$49.67M | $79.01M | $48.88M | +163.4% |
| EBITDA | $122.50M | $29.12M | $154.59M | $140.38M | +320.7% |
| Basic shares | 44.57M | 46.24M | 46.22M | 45.52M | -3.6% |
| Diluted shares | 45.04M | 46.24M | 51.98M | 46.54M | -2.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $158.54M | $276.77M | $153.30M | $104.14M | — | -42.7% |
| Cash & short-term investments | $238.42M | $484.62M | $278.58M | $288.65M | — | -50.8% |
| Accounts receivable | $124.07M | $113.30M | $105.56M | $98.40M | — | +9.5% |
| Inventory | $152.86M | $125.28M | $104.35M | $96.06M | — | +22.0% |
| Total current assets | $547.97M | $745.13M | $509.99M | $498.33M | — | -26.5% |
| Property, plant & equipment | $182.47M | $216.39M | $234.95M | $254.39M | — | -15.7% |
| Goodwill & intangibles | $388.31M | $425.97M | $646.50M | $703.79M | — | -8.8% |
| Total assets | $1.26B | $1.55B | $1.57B | $1.68B | — | -18.6% |
| Total current liabilities | $120.59M | $309.92M | $97.38M | $147.77M | — | -61.1% |
| Current debt | — | $201.78M | $8.64M | $33.65M | $374.70M | — |
| Long-term debt | $372.19M | $383.55M | $513.80M | $655.82M | — | -3.0% |
| Total debt | $418.20M | $638.85M | $586.04M | $763.39M | — | -34.5% |
| Total liabilities | $571.81M | $775.17M | $704.26M | $906.19M | — | -26.2% |
| Retained earnings | -$199.32M | -$206.36M | -$106.80M | -$148.75M | — | +3.4% |
| Shareholder equity | $693.11M | $778.35M | $870.13M | $775.01M | — | -11.0% |
| Working capital | $427.38M | $435.21M | $412.61M | $350.56M | — | -1.8% |
| Net tangible assets | $304.80M | $352.38M | $223.63M | $71.22M | — | -13.5% |
| Shares issued | 47.89M | 47.08M | 46.48M | 45.93M | — | +1.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $7.03M | -$99.56M | $41.95M | $15.91M | +107.1% |
| Depreciation & amortisation | $91.02M | $78.78M | $75.57M | $91.50M | +15.5% |
| Stock-based compensation | $57.50M | $51.17M | $47.90M | $48.09M | +12.4% |
| Change in working capital | -$38.27M | -$11.10M | -$41.20M | -$16.43M | -244.8% |
| Operating cash flow | $151.99M | $189.39M | $154.65M | $145.27M | -19.7% |
| Capital expenditure | -$15.33M | -$10.64M | -$15.16M | -$30.08M | -44.2% |
| Investing cash flow | $99.48M | -$83.28M | $77.54M | -$225.19M | +219.5% |
| Share buybacks | -$148.33M | -$25.00M | $0 | $0 | -493.3% |
| Financing cash flow | -$369.63M | $17.36M | -$183.03M | -$401.53M | -2,228.8% |
| Free cash flow | $136.66M | $178.75M | $139.49M | $115.20M | -23.5% |
| End cash position | $158.54M | $276.77M | $153.30M | $104.14M | -42.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $192.40M | $177.38M | $196.87M | $179.52M | $181.10M | +8.5% |
| Operating revenue | $192.40M | $177.38M | $196.87M | $179.52M | $181.10M | +8.5% |
| Cost of revenue | $44.16M | $36.41M | $40.30M | $34.28M | $40.87M | +21.3% |
| Gross profit | $148.24M | $140.96M | $156.57M | $145.24M | $140.23M | +5.2% |
| Research & development | $30.24M | $28.07M | $37.45M | $25.97M | $28.20M | +7.7% |
| Selling, general & admin | $91.81M | $93.94M | $101.61M | $91.80M | $88.58M | -2.3% |
| Total operating expense | $136.37M | $136.34M | $167.50M | $132.09M | $131.10M | +0.0% |
| Operating income | $11.86M | $4.63M | -$10.92M | $13.15M | $9.13M | +156.5% |
| Net interest income | -$1.68M | -$1.77M | -$1.60M | $4.25M | $313.00K | +5.1% |
| Pre-tax income | $2.56M | $5.00M | $571.00K | $9.52M | -$1.93M | -48.9% |
| Tax provision | -$2.10M | $2.08M | -$1.07M | $4.09M | $2.92M | -200.8% |
| Net income | $4.65M | $2.92M | $1.64M | $5.43M | -$4.85M | +59.6% |
| Net income to common | $4.65M | $2.92M | $1.64M | $5.43M | -$4.85M | +59.6% |
| Basic EPS | 0.12 | 0.07 | 0.04 | 0.12 | -0.11 | +71.4% |
| Diluted EPS | 0.12 | 0.07 | 0.04 | 0.12 | -0.11 | +71.4% |
| EBIT | $5.66M | $8.18M | $3.94M | $13.18M | $1.92M | -30.8% |
| EBITDA | $26.95M | $29.51M | $25.29M | $34.37M | $29.24M | -8.7% |
| Basic shares | 39.46M | 40.46M | 42.49M | 44.04M | 45.46M | -2.5% |
| Diluted shares | 40.30M | 40.91M | 42.98M | 44.46M | 45.46M | -1.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $205.88M | $144.31M | $158.54M | $147.59M | $300.48M | — | +42.7% |
| Cash & short-term investments | $251.03M | $202.18M | $238.42M | $246.33M | $445.86M | — | +24.2% |
| Accounts receivable | $132.42M | $125.64M | $124.07M | $115.27M | $114.37M | — | +5.4% |
| Inventory | $134.57M | $150.37M | $152.86M | $157.68M | $148.16M | — | -10.5% |
| Total current assets | $615.22M | $514.96M | $547.97M | $562.75M | $745.61M | — | +19.5% |
| Property, plant & equipment | $175.20M | $175.69M | $182.47M | $191.65M | $201.71M | — | -0.3% |
| Goodwill & intangibles | $305.13M | $373.00M | $388.31M | $402.71M | $442.86M | — | -18.2% |
| Total assets | $1.24B | $1.21B | $1.26B | $1.30B | $1.54B | — | +2.9% |
| Total current liabilities | $122.01M | $108.79M | $120.59M | $107.08M | $313.16M | — | +12.2% |
| Current debt | — | — | — | — | $202.40M | $202.09M | — |
| Long-term debt | $363.12M | $367.66M | $372.19M | $376.72M | $378.10M | — | -1.2% |
| Total debt | $412.12M | $411.18M | $418.20M | $425.31M | $631.40M | — | +0.2% |
| Total liabilities | $572.00M | $554.64M | $571.81M | $570.36M | $779.50M | — | +3.1% |
| Retained earnings | -$191.75M | -$196.41M | -$199.32M | -$200.96M | -$206.39M | — | +2.4% |
| Shareholder equity | $671.98M | $653.89M | $693.11M | $727.21M | $757.77M | — | +2.8% |
| Working capital | $493.20M | $406.17M | $427.38M | $455.67M | $432.45M | — | +21.4% |
| Net tangible assets | $366.85M | $280.89M | $304.80M | $324.50M | $314.90M | — | +30.6% |
| Shares issued | 39.82M | 48.33M | 47.89M | 47.74M | 46.30M | — | -17.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $4.65M | $2.92M | $1.64M | $5.43M | -$4.85M | +59.6% |
| Depreciation & amortisation | $21.30M | $21.33M | $21.34M | $21.19M | $27.32M | -0.2% |
| Stock-based compensation | $14.96M | $13.54M | $13.50M | $13.98M | $15.47M | +10.5% |
| Change in working capital | $16.49M | -$11.57M | $14.71M | -$19.25M | -$36.85M | +242.6% |
| Operating cash flow | $57.46M | $25.68M | $43.69M | $60.83M | $12.01M | +123.8% |
| Capital expenditure | -$1.34M | -$2.72M | -$218.00K | -$3.87M | -$2.70M | +51.0% |
| Investing cash flow | $11.76M | $19.44M | $19.33M | $43.61M | $62.16M | -39.5% |
| Share buybacks | $0 | -$50.05M | -$48.25M | -$50.04M | -$50.04M | +100.0% |
| Financing cash flow | -$7.65M | -$59.40M | -$51.65M | -$257.48M | -$57.51M | +87.1% |
| Free cash flow | $56.12M | $22.96M | $43.47M | $56.96M | $9.31M | +144.5% |
| End cash position | $205.88M | $144.31M | $158.54M | $147.59M | $300.48M | +42.7% |
Options analytics
Put / call volume
0.92
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
12.50
-49.5% from spot
ATM implied vol
1.6%
Nearest strike to spot
Skew (10% OTM)
-12.5%
Calls bid over puts
Call volume
12
Contracts, this expiry
Put volume
11
Contracts, this expiry
Heaviest call OI
25.00
0 contracts
Heaviest put OI
12.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.65 | 0.73 | +12.8% |
| Mar 2026 | 0.56 | 0.60 | +6.4% |
| Dec 2025 | 0.90 | 0.57 | -37.0% |
| Sep 2025 | 0.65 | 0.70 | +7.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.73 | 9 | $183.04M | +2.0% |
| Next quarter | 0.83 | 9 | $201.56M | +2.4% |
| Current year | 2.89 | 9 | $754.36M | +3.9% |
| Next year | 3.44 | 9 | $789.70M | +4.7% |
Analyst targets & ownership
Mean target$30.00
High target$38.00
Low target$23.00
Implied upside21.16%
Analyst count9
ConsensusBUY
Strong buy / Buy1 / 4
Hold3
Sell / Strong sell0 / 1
Held by insiders1.74%
Held by institutions113.13%
Institutions holding350
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
25.14
-1.52% from price
SMA 20
24.97
-0.86% from price
SMA 50
25.21
-1.79% from price
SMA 100
24.67
+0.38% from price
SMA 200
23.88
+3.67% from price
EMA 12
25.06
-1.18% from price
EMA 26
25.10
-1.37% from price
EMA 50
25.06
-1.22% from price
RSI (14)
46.4
Neutral
MACD (12,26,9)
-0.05
Hist -0.00
ATR (14)
0.78
3.17% of price
Realised vol 30D
28.2%
Annualised
Bollinger upper
25.90
20, 2σ
Bollinger lower
24.05
20, 2σ
50 / 200 cross
Golden
25.21 vs 23.88
Trend bias
Above 200
+3.67%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.30
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
28.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-28.2%
Peak to trough
Max drawdown 5Y
-85.7%
Peak to trough
ATR 14
0.78
3.17% of price
Beta (reported)
0.25
5Y monthly, from filing
Short interest
Shares short
7.56M
Prior 7.30M
Change vs prior
+3.6%
Shorts adding
% of float
27.27%
Heavily shorted
% of shares out
18.97%
Against total outstanding
Days to cover
14.8
Crowded exit
Float
36.19M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 26 | Oppenheimer | INITIATED | — | Outperform |
| Sep 9, 26 | Leerink Partners | INITIATED | — | Market Perform |
| Aug 5, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Aug 5, 26 | Needham | MAINTAINED | Buy | Buy |
| Jul 1, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 1, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| May 1, 26 | Needham | MAINTAINED | Buy | Buy |
| Mar 26, 26 | Barclays | MAINTAINED | Equal-Weight | Equal-Weight |
| Jan 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 9, 26 | Needham | MAINTAINED | Buy | Buy |
| Dec 9, 25 | Barclays | INITIATED | — | Equal-Weight |
| Nov 7, 25 | Truist Securities | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-30
Corporate Changes & Voting Matters
8-K · 2026-06-11
Proxy Statements
DEFA14A · 2026-06-04
Proxy Statements
DEFA14A · 2026-06-01
Proxy Statements
DEFA14A · 2026-05-28
Proxy Statements
DEFA14A · 2026-05-27
Proxy Statements
DEFA14A · 2026-05-26
Headlines
Pacira BioSciences (PCRX) On Its Molteni Deal And The Undervalued Narrative
Simply Wall St. · 10h ago
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
Zacks · 17h ago
Pacira partners with Molteni for Exparel commercialisation
Pharmaceutical Technology · 20h ago
Pacira Biosciences Grants Molteni Exclusive Rights to Commercialize EXPAREL in EU, UK
MT Newswires · 2d ago
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
GlobeNewswire · 2d ago
Oppenheimer Initiates Pacira Biosciences at Outperform With $32 Price Target
MT Newswires · 14d ago
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 28d ago
Leerink Partners Initiates Coverage on Pacira Biosciences With Market Perform Rating, $28 Price Target
MT Newswires · 28d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.